相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
Steven G. Chrysant et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E. Cobble et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
A. S. Abdelmoneim et al.
DIABETES OBESITY & METABOLISM (2012)
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
J. Wainstein et al.
DIABETES OBESITY & METABOLISM (2012)
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study
K. H. Yoon et al.
DIABETES OBESITY & METABOLISM (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
Wenying Yang et al.
JOURNAL OF DIABETES (2012)
Potential cardiovascular effects of incretin-based therapies
Carolyn F. Deacon et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2012)
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury
Yumei Ye et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
L. Olansky et al.
DIABETES OBESITY & METABOLISM (2011)
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study
M. Eliasson et al.
DIABETOLOGIA (2011)
Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents
B. B. Dokken et al.
HORMONE AND METABOLIC RESEARCH (2011)
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
A. Perez-Monteverde et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
K. H. Yoon et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
The Safety of Incretin-Based Therapies-Review of the Scientific Evidence
Daniel J. Drucker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study
Casper H. Jorgensen et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Role of the SDF-1/CXCR4 System in Myocardial Infarction
Masafumi Takahashi
CIRCULATION JOURNAL (2010)
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Philip A. Read et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2010)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Meghan Sauve et al.
DIABETES (2010)
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes Possible role of stromal-derived factor-1α
Gian Paolo Fadini et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) - Rationale, design and first interim analysis
Hans D. Theiss et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Kevin M. Pantalone et al.
ACTA DIABETOLOGICA (2009)
Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
Marc-Michael Zaruba et al.
CELL STEM CELL (2009)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes
Partha Kar et al.
CARDIOVASCULAR DRUGS AND THERAPY (2008)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Vascular disease and diabetes: is hypoglycaemia an aggravating factor?
Rohana J. Wright et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
Ananda Basu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes
JA Johnson et al.
DIABETIC MEDICINE (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
JJ Meier et al.
HEART (2004)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Impact of diabetes on long-term survival after acute myocardial infarction - Comparability of risk with prior myocardial infarction
KJ Mukamal et al.
DIABETES CARE (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
